Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Smith and Nephew's house broker counts cost of Dermagraft:

This article was originally published in Clinica

Executive Summary

Smith & Nephew shares fell to a three-year low, after its house broker, Dresdner Kleinwort Benson, forecast profits for the London-based company of £68 million ($109 million) in the half-year to June, down from £81 million the previous year. S&N committed $35 million to Advanced Tissue Sciences, its partner for the artificial skin product, Dermagraft, in January, but the FDA says a new clinical trial is needed before the product can be approved for diabetic foot ulcers (see Clinica Nos 812, p 14 & 792, p 9). In addition, S&N has seen the strong value of sterling and the US dollar affect its profits over the past 18 months.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts